指南与共识造血干细胞移植与细胞治疗

血液系统恶性肿瘤干细胞移植后移植物抗宿主病的预防与管理:欧洲血液与骨髓移植学会更新版共识推荐

Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation.
指南 / 共识 · Lancet Haematol · 2024-01-03

欧洲血液与骨髓移植学会(EBMT)更新了异基因造血干细胞移植后移植物抗宿主病(GVHD)的临床实践推荐。工作组由1名方法学家和22名专家组成,采用GRADE流程对10个PICO问题分级并在两次共识会议上投票。关键更新包括:芦可替尼作为激素难治性急性及慢性GVHD的一线标准治疗;兔抗T细胞(胸腺细胞)球蛋白或移植后环磷酰胺作为无关供者外周血干细胞移植的标准GVHD预防;belumosudil新增为激素难治性慢性GVHD的治疗选择。

要点

  • 芦可替尼成为激素难治性急性GVHD和激素难治性慢性GVHD的新标准治疗。
  • 无关供者外周血干细胞移植中,兔抗T细胞球蛋白或移植后环磷酰胺可作为标准GVHD预防。
  • belumosudil新增为激素难治性慢性GVHD的治疗选择之一。

核心结论

  • EBMT建议将这些推荐作为异基因造血干细胞移植中GVHD常规管理的基础。
  • 当前推荐倾向于欧洲实践,不一定代表全球偏好。

研究设计与样本

  • EBMT组建了由1名方法学家和22名GVHD管理领域专家组成的工作组,专家选择基于其在欧洲GVHD管理中的角色及发表、会议报告等贡献。
  • 应用GRADE流程对10个PICO(患者、干预、对照、结局)问题进行证据检索,并对每个关键结局进行分级。
  • 在两次共识会议上讨论证据并对推荐措辞和强度进行投票。

主要发现

  • 关键更新包括:芦可替尼作为激素难治性急性GVHD和激素难治性慢性GVHD的一线治疗,成为新的标准治疗。
  • 关键更新包括:兔抗T细胞(胸腺细胞)球蛋白或移植后环磷酰胺可作为无关供者外周血干细胞移植的标准GVHD预防。
  • 关键更新包括:belumosudil新增为激素难治性慢性GVHD的可用治疗选择之一。

关键数值与推荐

  • 芦可替尼作为激素难治性急性GVHD和激素难治性慢性GVHD的一线标准治疗。
  • 兔抗T细胞(胸腺细胞)球蛋白或移植后环磷酰胺作为无关供者外周血干细胞移植的标准GVHD预防。
  • belumosudil新增为激素难治性慢性GVHD的治疗选择之一。

临床怎么用

  • EBMT建议将这些推荐作为异基因造血干细胞移植中GVHD常规管理的基础。

局限性

  • 当前推荐倾向于欧洲实践,不一定代表全球偏好。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Graft-versus-host disease (GVHD) is a major factor contributing to mortality and morbidity after allogeneic haematopoietic stem-cell transplantation (HSCT). In the last 3 years, there has been regulatory approval of new drugs and considerable change in clinical approaches to prophylaxis and management of GVHD. To standardise treatment approaches, the European Society for Blood and Marrow Transplantation (EBMT) has updated its clinical practice recommendations. We formed a panel of one methodologist and 22 experts in the field of GVHD management. The selection was made on the basis of their role in GVHD management in Europe and their contributions to the field, such as publications, presentations at conferences, and other research. We applied the GRADE process to ten PICO (patient, intervention, comparator, and outcome) questions: evidence was searched for by the panel and graded for each crucial outcome. In two consensus meetings, we discussed the evidence and voted on the wording and strengths of recommendations. Key updates to the recommendations include: (1) primary use of ruxolitinib in steroid-refractory acute GVHD and steroid-refractory chronic GVHD as the new standard of care, (2) use of rabbit anti-T-cell (thymocyte) globulin or post-transplantation cyclophosphamide as standard GVHD prophylaxis in peripheral blood stem-cell transplantations from unrelated donors, and (3) the addition of belumosudil to the available treatment options for steroid-refractory chronic GVHD. The EBMT proposes to use these recommendations as the basis for routine management of GVHD during allogenic HSCT. The current recommendations favour European practice and do not necessarily represent global preferences.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Penack O, Marchetti M, Aljurf M, et al. Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematol. 2024. PMID: 38184001. doi:10.1016/S2352-3026(23)00342-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。